Jan 2, 2025, 15:18
Akhil Santhosh: Can SCLC molecular subtypes guide therapy?
Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, posted on X:
“Can SCLC molecular subtypes guide therapy?
1. ASCL1: anti DLL3 based therapy, sensitivity to PARPi
2. Pou2F3: sensitivity to parpi
3 I- Inflamed subtype: sensitivity to IO+
4. NeuroD1: MYC targeting may help, responses observed with Aurora kinase inhibitors.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 4, 2025, 16:17
Sep 4, 2025, 16:08
Sep 4, 2025, 15:59
Sep 4, 2025, 15:51
Sep 4, 2025, 15:49
Sep 4, 2025, 15:48
Sep 4, 2025, 15:36